Brief: Everest Medicines Says Unit Entered Into License Agreement With Sinovent And Sinomab
16/09/2021 23:09
Sept 17 (Reuters) - Everest Medicines Ltd 1952.HK :
* EVEREST MEDICINES LTD - UNIT ENTERED INTO LICENSE
AGREEMENT
WITH SINOVENT AND SINOMAB
* EVEREST MEDICINES LTD - SINOVENT AND SINOMAB GRANTED
EVEREST HK
AN EXCLUSIVE, SUBLICENSABLE LICENSE TO DEVELOP, MANUFACTURE AND
COMMERCIALIZE XNW1011
Source text for Eikon: ID:
Further company coverage: 1952.HK
(Reuters.briefs@thomsonreuters.com)
Recent news on Everest Medicines
See all newsBrief: Everest Medicines Says NMPA Approves Cardamyst (Etripamil) NDA For PSVT In Adults In China
Brief: Everest Medicines Enters Commercialization Collaboration With Hainan Herui Pharmaceutical
Brief: Everest Medicines Says CBC Group Purchases 712,000 Everest Medicines Shares For Hk$19.2 Million From 16 To 17 June
Australia's Dimerix soars on commercialisation deal with Everest Medicines
Brief: Dimerix Ltd Licenses Dmx200 To Everest For China And Asia Region